{
  "abstract": "Purpose\n\nTo investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy in patients with esophageal cancer.Methods\n\nFrom July 2020 to October 2023, 15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. The incidence of adverse reactions was recorded throughout the treatment period. The Kaplan-Meier survival analysis was used to estimate median overall survival (OS) and progression-free survival (PFS).Results\n\nAll 15 patients were enrolled, with a median follow-up of 23.0 months (ranging from 6.0 to 37.5 months). The 1-year OS rate was 93.3%, and the 2-year OS rate was 46.7%. No treatment-related deaths were reported.Conclusion\n\nConcurrent chemoradiotherapy combined with PD-1 antibody yielded encouraging survival outcomes in patients with esophageal cancer, and this regimen deserves further clinical exploration.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiation Oncology, Zhejiang Medical & Health Group Quzhou Hospital (Zhejiang Quhua Hospital), Quzhou, 324004, Zhejiang, China.",
    "Department of Radiation Oncology, Zhejiang Medical & Health Group Quzhou Hospital (Zhejiang Quhua Hospital), Quzhou, 324004, Zhejiang, China. realhtme@163.com."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Chunxiu Hu"
    },
    {
      "affs": [
        0
      ],
      "name": "Yi Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhengqi Yang"
    },
    {
      "affs": [
        0
      ],
      "name": "Qin Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuefang Tong"
    },
    {
      "affs": [
        0
      ],
      "name": "Bin Da"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuefei Sun"
    },
    {
      "affs": [
        1
      ],
      "name": "Huiting Rao",
      "orcid": "0000-0003-0001-5643"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8kkqxzj2jqa4n.bib",
  "cited_by": 0,
  "doi": "10.1186/s13019-026-04502-1",
  "fulltext_url": "https://europepmc.org/articles/PMC13679255",
  "id": "8kkqxzj2jqa4n",
  "issns": [
    "1749-8090"
  ],
  "landing_url": "https://europepmc.org/article/MED/42894226",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RD1-811"
    ],
    [
      "lcc",
      "RD78.3-87.3"
    ],
    [
      "openalex",
      "2746|Esophageal Cancer Research and Treatment"
    ]
  ],
  "openalex": "W7170054860",
  "pdf_url": "https://europepmc.org/articles/PMC13679255?pdf=render",
  "pmcid": "PMC13679255",
  "pmid": "42894226",
  "published": "2026-07-01",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/8kkqxzj2jqa4n.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:42Z",
      "native_id": "MED:42894226",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42894226"
    },
    {
      "first_seen": "2026-10-30T13:46:20Z",
      "native_id": "3b71036740a940f7b137936dc1a49536",
      "source": "doaj",
      "url": "https://doi.org/10.1186/s13019-026-04502-1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Esophageal Cancer Research and Treatment",
      "subfield": "surgery"
    }
  ],
  "title": "Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.",
  "title_text": "Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:20Z",
  "url": "https://research.draconitic.com/paper/8kkqxzj2jqa4n",
  "venue": "Journal of cardiothoracic surgery",
  "versions": []
}